Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Patient Education
Share your love
Unmet Needs in Dry Eye Disease | Ophthalmology Times
The Viewpoints series “Reimagining Dry Eye Management: Targeting Tear Function for Sustained Relief” convenes leading experts in ophthalmology and optometry to discuss evolving perspectives on dry eye disease (DED). Under the moderation of Kendall Donaldson, MD, MS, the panel—comprising Cecelia…
Management and Monitoring Strategies in Dry Eye Disease | Ophthalmology Times
The Viewpoints series “Reimagining Dry Eye Management: Targeting Tear Function for Sustained Relief” convenes leading experts in ophthalmology and optometry to discuss evolving perspectives on dry eye disease (DED). Under the moderation of Kendall Donaldson, MD, MS, the panel—comprising Cecelia…
Malar edema: Perspectives from plastic surgery and ophthalmology | Ophthalmology Times
(Image Credit: AdobeStock/Alessandro Grandini) Malar edema, the collection of fluid below the infraorbital rim and over the malar eminence, presents a unique challenge to providers in aesthetics and ophthalmology.1 Despite their seemingly benign nature, the presence of malar edema or…
Spotlight on women’s health: Understanding thyroid eye disease | Ophthalmology Times
Image by Jennifer Toomey/MJH Life Sciences using AI Thyroid eye disease (TED), also known as Graves ophthalmopathy or Graves eye disease, is an autoimmune condition in which the immune system targets tissues related to the thyroid.1 This leads to inflammation…
Enhancing Durability and Fluid Control with Aflibercept 8 mg in Retinal Vascular Diseases | Ophthalmology Times
This discussion centers on real-world comparisons between aflibercept 2 mg and the newer 8 mg formulation, focusing on drying efficacy, durability, and patient experience. Clinicians agree that aflibercept 8 mg offers a clear advantage in retinal fluid control and treatment…
Evolving Therapeutic Strategies with Next-Generation Anti-VEGF Agents in Retinal | Ophthalmology Times
This segment examines how the advent of higher-dose and dual-pathway anti-VEGF agents has reshaped treatment strategies for retinal vascular diseases. The discussion underscores how aflibercept 8 mg and faricimab have improved anatomic outcomes and extended dosing intervals, offering meaningful—though patient-specific—reductions…
Managing challenging pterygium removal: Amniotic membrane grafting strategies | Ophthalmology Times
(Image Credit: AdobeStock/Sangiao_Photography) Pterygium is a common ocular surface disorder characterized by a fibrovascular growth originating from the conjunctiva that extends onto the adjacent cornea (Figure).1 Its prevalence varies considerably across geographic regions. Because prolonged sun exposure is the main…
Argenx discontinues phase 3 UplighTED trials of efgartigimod SC in thyroid eye disease | Ophthalmology Times
(Image Credit: AdobeStock/SnapVault) Argenx SE has discontinued the phase 3 UplighTED studies evaluating efgartigimod subcutaneous (SC) (efgartigimod alfa and hyaluronidase-qvfc) in adults with moderate to severe thyroid eye disease (TED). According to the company, the trial is being discontinued based…
Advantages of Neurogenic Stimulation and Identifying Ideal Dry Eye Candidates for Acoltremon | Ophthalmology Times
The Viewpoints series “Reimagining Dry Eye Management: Targeting Tear Function for Sustained Relief” convenes leading experts in ophthalmology and optometry to discuss evolving perspectives on dry eye disease (DED). Under the moderation of Kendall Donaldson, MD, MS, the panel—comprising Cecelia…
The Role of TRPM8 Agonists in Dry Eye Disease | Ophthalmology Times
The Viewpoints series “Reimagining Dry Eye Management: Targeting Tear Function for Sustained Relief” convenes leading experts in ophthalmology and optometry to discuss evolving perspectives on dry eye disease (DED). Under the moderation of Kendall Donaldson, MD, MS, the panel—comprising Cecelia…